Patents by Inventor Lars Michael Wood

Lars Michael Wood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy
    Publication number: 20020025925
    Abstract: The invention relates to the use of a matrix metalloproteinase inhibitor and a cyclosporin in combination therapy for treating mammals suffering from arthritic diseases such as rheumatoid arthritis.
    Type: Application
    Filed: May 9, 2001
    Publication date: February 28, 2002
    Inventors: Lars Michael Wood, David Olum Laber, Annette Wright
  • Release and mobilization of haematopoietic cells
    Patent number: 5925568
    Abstract: Stem cell inhibitors such as murine and human macrophage inflammatory protein-1alpha (muMIP-1alpha and huMIP-1alpha/LD78) and their analogues and variants enhance the release and mobilization of haematopoietic cells. This property makes them useful in enhancing responses against infection and in cell harvesting.
    Type: Grant
    Filed: January 16, 1996
    Date of Patent: July 20, 1999
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Michael Berisford Comer, Matthew John McCourt, Lars Michael Wood, Michael George Hunter, Richard Mark Edwards
  • Heterocyclic sulfonamide derivatives as antagonists of PAF and angiotensin II
    Patent number: 5741794
    Abstract: Compounds of formula (I), wherein: A represents: a) a --VR.sup.6 group wherein v is --C(.dbd.O), --C(.dbd.O)O--, --CH.sub.2 O--, --CH.sub.2 OC(.dbd.O)--, --C(.dbd.S)--, --CH.sub.2 OC(.dbd.O)NH--, --C(.dbd.S)O--, --CH.sub.2 S--, --C(.dbd.O)NHSO.sub.2 --, --SO.sub.2 NHC(.dbd.O)-- or --CH.sub.2 OSiPh.sub.2 --; b) a --CH.sub.2 NR.sup.9 R.sup.10 group or a --CONR.sup.9 R.sup.10 group wherein each of R.sup.9 and R.sup.10 is independently hydrogen, -alkyl-, -alkenyl-, -alkynyl, -cycloalkyl, -cycloalkenyl, pyridyl (any of which may optionally be substituted) or a group --D as defined above or R.sup.9 and R.sup.10 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring; c) a group Y where Y is a 5- or 6-membered optionally substituted heterocyclic ring containing one or more heteroatoms selected from nitrogen, oxygen and sulphur; or d) a group --CH.sub.2 Y or --C(.dbd.
    Type: Grant
    Filed: September 1, 1994
    Date of Patent: April 21, 1998
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Stephen Arthur Bowles, Christopher David Floyd, Andrew Miller, Mark Whittaker, Lars Michael Wood
  • Thrombolytic composition
    Patent number: 5741771
    Abstract: The invention disclosed relates to thrombolytic combination therapy by the administration of an agent capable of activating native plasminogen, and a non-native plasminogen analogue which is cleavable by native thrombin to generate plasmin activity.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: April 21, 1998
    Assignee: British Biotech Pharmaceuticals Ltd.
    Inventors: Keith Martyn Dawson, Lars Michael Wood, Michael Berisford Comer